Abbott, AZ Advance Cholesterol Combo Drug

Abbott and AstraZeneca will advance the development of Abbott’s next-generation fenofibrate ABT-335 and AZ’s Crestor (rosuvastatin calcium) in a fixed-dose combination treatment into Phase III trials. The single pill would target all three major blood lipids: LDL-C “bad” cholesterol, HDL-C “good” cholesterol, and triglycerides.

Abbott’s ABT-335, currently in late-stage clinical trials, is part of a class of medications called fibrates, which have been shown to raise HDL-C, reduce triglycerides and moderately lower LDL-C. Based on the progress with the ABT-335 and Crestor fixed-dose combination program, the companies have decided to move forward with this combination therapy. The studies are proceeding on schedule.

“AstraZeneca is committed to continually investigate new treatment options for patients at risk for cardiovascular disease,” said James Blasetto M.D., vice president, strategic development, AstraZeneca. “The combination of Crestor and ABT-335 may be an important option to help patients with mixed dyslipidemia achieve their treatment goals.”

Abbott will continue the clinical trial program and is responsible for regulatory registration of the combination drug, which is targeted for submission in 2009. AZ will hold the NDA. The collaboration pertains to the U.S. market.